Anti-yeast activity of extracts and fractions from Uvariodendron calophyllum (Annonaceae) by Menkem, Elisabeth Zeuko’o et al.
 
Available online at http://www.ifg-dg.org 
 
Int. J. Biol. Chem. Sci. 9(6): 2500-2522, December 2015 
 
ISSN 1997-342X (Online),  ISSN 1991-8631 (Print)  
 
 
© 2015 International Formulae Group. All rights reserved.                                                             2504-IJBCS 
DOI : http://dx.doi.org/10.4314/ijbcs.v9i6.1 
Original Paper      http://ajol.info/index.php/ijbcs          http://indexmedicus.afro.who.int 
 
Anti-yeast activity of extracts and fractions from Uvariodendron calophyllum 
(Annonaceae) 
 
Elisabeth Zeuko’o MENKEM1, Rufin Marie Toghueo KOUIPOU1,  
Cedric Derick Jiatsa MBOUNA1, Paul Toukam  DJOUONZO2,3,  
Thierry Ngouana KAMMALAC1, Patrick Valere TSOUH FOKOU1  
and Fabrice Fekam BOYOM1* 
 
1Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, Department of 
Biochemistry, University of Yaoundé 1, P. O. Box 812, Yaoundé, Cameroon. 
2Department of Organic Chemistry, University of Yaoundé 1, Cameroon, P.O Box 812, Yaoundé, Cameroon. 
3Institute of Medical Research and Medicinal Plant Studies (IMPM), P.O Box 6163, Yaoundé, Cameroon. 
* Corresponding author; E-mail: fabrice.boyom@fulbrightmail.org ;Tel.: +237-677-276-585 
 
 
ABSTRACT      
 
The resistance to available antifungals highlights t e urgent need for innovative drugs to treat yeasts 
infections. This study aimed at evaluating the activity of extracts and fractions from Uvariodendron 
calophyllum against pathogenic yeasts. The ethanolic and aqueous extracts obtained by maceration were liquid-
liquid-partitioned using organic solvents and screened against isolates of Candida albicans, Candida glabrata, 
Candida parapsilosis, Cryptococcus neoformans and Candida albicans reference strains NR-29445, NR-
29444, NR-29451, and NR-29450 from BEI Resources using the broth micro-dilution method. Time kill 
kinetic, inhibition of germ-tube, filamentation and chlamydosporulation, and biofilm formation were assessed 
using the best sub-fraction. Overall, the most interesting sub-fraction (FS: 237–253) showed an MIC value of 
0.0625 mg/mL with cidal effect against C. albicans NR-29450 and NR-29445 at 0.25 mg/mL after 12-16 hours 
and 24 hours respectively. Moderate inhibitory effects were observed at 0.25 mg/mL against germ-tube 
formation, filamentation and chlamydosporulation of all C. albicans strains. Also, very moderate inhibition of 
biofilm formation by C. albicans NR-29450 at 0.25 mg/mL was obtained. The results obtained support U. 
calophyllum as a potential source of compounds with anti-yeast activity. Further studies will confirm its 
potential as source of anti-yeast drugs. 
© 2015 International Formulae Group. All rights reserved. 
 
Keywords: Uvariodendron calophyllum, anti-yeasts activity, time kill kinetics, biofilm. 
 
 
INTRODUCTION      
Candida spp. are the most common 
cause of fungal infections leading to a range 
of  diseases from muco-cutaneous to invasive 
life-threatening systemic infections that can 
spread via the bloodstream to organs 
throughout the body (Jacqueline and Bettina, 
2010 ; Moran et al., 2012; Al-Ahmadey and 
Mohamed, 2014). Candidiasis has emerged as 
an alarming opportunistic disease as there is 
an increase in number of patients who are 
immuno-compromised, aged, receiving 
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prolonged antibacterial and aggressive 
anticancer chemotherapy or undergoing 
invasive surgical procedures, organ 
transplantation and HIV patients (Mohandas 
and   Ballal, 2011). The number of clinical 
infections worldwide has risen considerably in 
recent years   with about 9.5 million HIV 
patients suffering from oral candidiasis (The 
Fungal Research Trust, 2011). Other studies 
have shown that approximately 90% of 
HIV/AIDS infected persons have at one point 
demonstrated oropharyngeal colonization by 
Candida species (De Repentigny et al., 2004). 
Epidemiological studies showed that in 
Cameroon, the prevalence of candidiasis 
amongst HIV/AIDS patients is 67.8% with C. 
albicans being responsible for 42.8% of cases 
(Njunda et al., 2012; Njunda et al., 2013).   
Furthermore, mortality in patients with 
candidemia is high, ranging from 40% to 
60%, with reported attributable mortality of 
20–40% (Méan et al., 2008). Although C. 
albicans is still considered the most prevalent 
pathogen within the Candida clade, non-
 albicans Candida species are increasingly 
being isolated from patients, with C. 
glabrata,  C. parapsilosis  and  C. 
tropicalis being the most represented ones 
(Peng and Lu, 2013). In addition, 
Cryptococcus neoformans i  a human 
opportunistic fungal pathogen causing severe 
disseminated meningoencephalitis, mostly in 
patients with cellular immune defects. 
Overall, significant part of this prevalence is 
due to the increase incidence of resistance to 
conventional antifungal therapies (Lai et al., 
2008). In addition, drug-related toxicity and 
high cost of available antifungals has 
encouraged the search for alternative 
treatment from natural products 
(Duraipandiyan and Ignacimuthu, 2008). 
Many plant-derived products have gained 
interest for use as alternatives to traditional 
antimicrobials, since these extracts are widely 
believed to be safe and have a long history of 
use in folk medicine for the prevention and 
treatment of diseases (Das et al., 2010). 
  Plants from the Annonaceae family 
are used in traditional medicine to treat many 
infectious diseases including microbial 
infections. The fruits and seeds of some of 
these plants are used as decoction for the 
treatment of dermatitis and liver disorders in 
the southwest and littoral regions of 
Cameroon (Jiofack et al., 2010). Specifically, 
U. calophyllum is used in traditional medicine 
for the treatment of infectious diseases and 
has been shown to possess antifungal and 
antioxidant activities (Zeuko’o et al., 2012). 
Based on this background, this study was 
designed to assess the activity of extracts of 
leaves, twigs, stem, and stem bark of U.
calophyllum against isolates of Candida 
albicans, Candida glabrata, Candida 
parapsilosis, Cryptococcus neoformans and 
Candida albicans reference strains NR-29445, 
NR-29444, NR-29451, and NR-29450 
obtained from BEI Resources following a bio-
guided fractionation strategy. Inhibition of the 
morphological stages of C. albicans NR-
29445 and NR-29450 was also assessed for 
the most promising extract sub-fraction.  
 
MATERIALS AND METHODS     
Collection and extraction of the plant 
materials  
The leaves, twigs, stem bark, and stem 
of U. calophyllum were collected at Mount 
Kalla in Yaoundé (Cameroon) on 11th 
September 2011 and a voucher specimen 
deposited at the National Herbarium of 
Cameroon, Yaoundé under the identification 
number 28734/SFR/CAM. The plant parts 
were individually dried at room temperature, 
and then ground to fine powder. Five hundred 
grams (500 g) of each sample were macerated 
with regular stirring in 2L of 95% Ethanol for 
72 h. The filtrate was evaporated using a 
rotary evaporator (Rotavapor BÜCHI 011). 
The plant residues from ethanol extraction 
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were dried and subsequently macerated in 
distilled water for 72 hours and the filtrate 
dried at Room Temperature (25-28 °C) under 
ventilation. The yields of extraction were 
calculated in percentage relative to the weight 
of the starting plant material.  
 
Bio-guided fractionation of crude extracts 
Extracts fractionation 
The dried ethanolic and aqueous 
extracts were individually dissolved in water 
at 10 g/100 mL and subsequently partitioned 
as previously described (Bolou et al., 2011). 
Briefly, the extracts dissolved in water were 
successively washed using equal volumes 
(100 mL) of hexane, methylene chloride, and 
methanol to afford hexane fraction, methylene 
chloride fraction, methanolic fraction, and 
H2O/CH2Cl2 interfaces for aqueous extracts. 
The solvents were separately evaporated 
under reduced pressure and the extracts 
screened against yeasts. Following our 
progression criteria, the methylene chloride 
fraction of the leaf ethanolic extract (UCl 
EtOH CH2Cl2) which showed the overall best 
anti-yeast activity was selected and subjected 
to silica gel column chromatography coupled 
with biological screening as described below. 
The column elution was done using solvent 
systems of increasing polarities, Hexane-Ethyl 
Acetate [100:0 – 0:100] and Ethyl Acetate -
Methanol [95:5- 0:100]. Two hundred and 
fifty-three (253) sub-fractions of 100 mL each 
were collected and evaporated to dry, and 
subsequently pooled on the basis of their thin 
layer chromatography (TLC) profiles into 
nineteen (19) major sub-fractions FA-FS (FA: 
1–11; FB: 12–17; FC: 18–28; FD: 29–35; FE: 
36–50; FF: 51–57; FG: 58–64; FH: 65–81; FI: 
82–86; FJ: 87–98; FK: 99–111; FL: 112–117; 
FM: 118–126; FN: 127–133; FO: 134–155; 




Determination of the anti-yeast activity 
C. albicans, C. glabrata, C. 
parapsilosis, and Cr. neoformans isolates 
obtained from HIV positive patients 
presenting at the Yaoundé Central Hospital 
(Cameroon), and developing various 
candidiasis (vaginal, oro-pharyngeal, 
intestinal, urinary) and cryptococcal 
meningitis were used for the experiments. No 
additional data or samples other than those 
collected during routine activity at the 
Yaoundé Central Hospital (YCH) laboratories 
were used during this study. Therefore, 
neither ethical approval nor patient consensus 
was considered necessary. Briefly, isolates 
were identified at YCH using routine 
conventional methods including macroscopic 
and microscopic morphology in conjunction 
with biochemical analyses. In addition, four 
C. albicans reference strains NR-29445, NR-
29444, NR-29451, and NR-29450 provided by 
BEI Resources NIAID, NIH were used for the 
study. 
Inoculum of each yeast isolate and 
strain was prepared from a 2 days old culture 
on Sabouraud Dextrose Broth (SDB) at 37 °C. 
The suspension was adjusted to 2.5x 103 
cells/mL using sterile 0.9% sodium chloride 
solution (normal saline) and Malassez 
counting chamber under an optical 
microscope (HumaScope Light, Human)  as 
previously described (Ngono et al., 2000).The 
broth micro-dilution method was used to 
assess yeast susceptibility to extracts 
according to the CLSI M27-A3 methodology 
(CLSI, 2008).  Briefly, each extract residue 
obtained from partition and column 
chromatography was dissolved at 100 mg/mL 
in 10% DMSO in SDB and serially diluted 
using SDB in 96-well plates. Positive control 
consisted of Nystatin (Novadina 
Pharmaceutical Ltd, London, United 
Kingdom) at 10 mg/mL. 20 µL of inoculum 
standardized at 2.5 × 103 cells/mL were added 
into each well to achieved a final volume of 
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120 µL. The final tested plant product 
concentrations ranged between 0.029 - 30 
mg/mL for the crude extracts, 0.0097-10 
mg/mL for fractions, and 0.00195 – 2 mg/mL 
for column chromatography sub-fractions. 
Nystatin was tested at 0.0029 - 3 mg/mL. 
Negative control wells consisted of 
inoculum with equivalent volume of 10% 
DMSO and no drugs added. After 48 h of 
incubation at 37 °C, the lowest concentration 
with no visual change in turbidity (indicating 
no growth of microorganism) was considered 
as the Minimum Inhibitory Concentration 
(MIC). The Minimum Fungicidal 
Concentration (MFC) was determined by sub-
culturing 25 µL aliquots of the clear wells into 
100 µL of freshly prepared broth medium and 
incubating at 37 °C for 48 h. The lowest 
concentration of test sample showing no 
turbidity change was considered as MFC. . 
Wells without inoculum or extract were 
included in each plate to control the 
background sterility and growth. 
The type of antifungal effect of extract 
or fraction was deduced from the calculated 
MFC/MIC ratio, and identified as fungicidal 
when MFC/MIC ≤ 4, or fungistatic when 
MFC/MIC > 4 (Carbonnelle et al., 1987). 
Based on activity criteria (MIC, MFC), sub-
fraction FS: 237-253 was selected and 
submitted to further detailed studies as 
described below.  
 
Mechanisms of anti-yeast action of sub-
fraction FS: 237 -253  
Time-kill kinetic assay 
The time-kill kinetic assay of sub-
fraction FS: 237-253 against C. albicans NR-
29445 and NR-29450 was performed as 
described by (Klepser et al., 1998), with some 
modifications. Inocula were prepared from 
two days-old cultures using Sabouraud 
Dextrose Broth culture medium and adjusted 
to 5 x 105 CFU/mL using the Malassez 
counting cell. 
One milliliter of fungal suspension was 
added to 9 mL of broth with or without the 
plant sub-fraction at concentrations of 
0.03125, 0.0625, 0.125, and 0.25 mg/mL. Test 
solutions were placed on an orbital shaker and 
incubated with agitation at 37 °C and for 
various time periods (0, 2, 4, 8, and 24 h). At 
predetermined time points, 50 µL aliquots 
were taken from each culture, and mixed with 
50 µL of methylene blue at 1mg/mL for 
determination of viable colony forming units 
(CFU) using the Malassez counting cell. 
Experiments were performed in duplicate. The 
log10 CFU/mL was plotted on a graph as 
function of time and used to compare the rate 
of fungal death at various concentrations of 
plant sub-fraction. The effect of the sub-
fraction was considered fungicidal when the 
number of cells was lower than or equal to 3 
log10 CFU/mL of the initial inoculum, 
corresponding to reduction of ≥ 99.9% 
CFU/mL. When the number of cells was 
greater than 3 log10 CFU/mL, the effect was 
considered fungistatic (Lewis et al., 2000). In 
addition, the effects of the sub-fraction on C. 
albicans morphology were observed.  
Effect of sub-fraction FS: 237 -253 on germ-
tube formation  
The same concentrations used for time-
kill kinetics assay were prepared in sterile 
fetal bovine serum and 50 µl of C. albicans 
NR-29445 and NR-29450 suspensions (1 × 
103 CFU/mL) were individually added. 
Nystatin was used as positive control and 
serum without inhibitor as negative control. 
The so-prepared mixtures were incubated at 
37 °C for 4 h, and germ-tubes formation and 
morphological changes were subsequently 
observed using an optical microscope (Kim 
and Lee, 2012). Germ-tubes were considered 
positive when they were at least as long as the 
blastospores. Protuberances showing a 
constriction at the point of connection to the 
mother cell, typical for pseudohyphae, were 
excluded.   
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Effect of sub-fraction FS: 237 -253 on 
filamentation and chlamydosporulation 
 The effect of sub-fraction FS: 237 -253 
on filamentation and chlamydosporulation of 
C. albicans NR-29445 and NR-29450 was 
determined by agar dilution method. Briefly, 
Potatoes Carrot Bile (PCB) and Rice Agar 
Tween were prepared and individually 
distributed at 15 mL each in test tubes and 
sterilized at 121 °C for 15 min. After 
sterilization, culture media were maintained in 
water bath at 40 °C and equivalent volumes of 
sub-fraction FS : 237 -253 in distilled water 
were introduced to achieve final 
concentrations of 0.03125, 0.0625, 0.125, and 
0.25 mg/mL. The mixtures were homogenized 
and poured in Petri Dishes and allowed to 
solidify for 15 min. Nystatin was used as 
positive control.  After solidification, the 
inoculum solution prepared at 2.5 x103 
cells/mL was seeded in semi-deep manner and 
incubated at 25 °C for 72 h. Cultures without 
inhibitor were used as negative control. 
Filamentation and chlamydosporulation were 
thereafter determined by observation using the 
light microscope. The experiments were 
performed in duplicate. 
 Determination of the antibiofilm properties 
of sub-fraction FS: 237 -253  
 Biofilm quantification and inhibition 
Biofilm forming ability of C. albicans 
NR-29450 was assessed using yeast nitrogen 
base (YNB) medium supplemented with 5% 
glucose. Quantification of biofilm was 
performed through total biomass using crystal 
violet (CV) staining on microtiter plates. After 
washing, biofilms were fixed with 200 µl of 
99% methanol, which was removed after 15 
min of contact. The microtiter plates were 
allowed to dry at room temperature, and 200 
µl of CV (1% v/v) added to each well and 
incubated for 5 min. The wells were then 
gently washed with sterile double-distilled 
water (DD-water) and 200 µl of acetic acid 
(33% v/v) added to wash out the stain. The 
absorbance of the obtained solution was 
recorded using a microtiter plate reader 
(BioTek Synergy HT, Izasa, Lisbon, Portugal) 
at 590 nm. Optical density was directly 
proportional to the quantity of biofilm in each 
well (Silva et al., 2009). The experiments 
were performed in duplicate. 
The inoculum of C. albicans NR-29450 
was prepared from a 2 days-old culture on 
SDA at 37 °C. The suspension was adjusted to 
1 x 103 cells/mL using YNB medium 
supplemented with 5% glucose from 0.5 
MacFarland standards.  
Briefly, the sub-fraction was serially 
diluted in YNB in flat-bottomed 96-well 
plates (MBECTM Biofilm Inoculator 
innovotech product panel P and G panel lot: 
14040004) and tested at concentrations of 
0.03125, 0.0625, 0.125, and 0.25 mg/mL. 
Eighty µL of inoculum standardized at 1 × 103 
cells/mL were added into each well to achieve 
a final volume of 230 µL. Candida biofilms 
were formed by immersing the pegs of the 
cover lid into the biofilm growth plate, 
followed by incubation at 37 °C for 20 h-24 h 
without shaking. Peg lids were rinsed three 
times in sterile DD-water, placed onto new 
flat-bottomed microtiter plates containing 150 
µL of YNB per well, and incubated for 18 h to 
20 h at 37 °C. After incubation, peg lids were 
rinsed again three times in sterile DD-water 
and placed into extract-free YNB in a flat-
bottomed microtiter plate (biofilm recovery 
plate). To transfer biofilms from pegs to wells, 
each plate was sonicated at room temperature 
for 20 min using a Bransonic 220 sonicator 
(BransonCo. Shelton, Conn.). The peg lid was 
discarded and replaced by a standard lid. The 
plates were then incubated at 37 °C for 24 h, 
visually observed and optical density read. A 
growth control containing microorganism and 
culture medium and a blank with only 
medium were included. Directly proportional 
optical densities were recorded in each well as 
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described above and plotted versus 
corresponding sub-fraction concentrations. 
Qualitative phytochemical analysis and thin 
layer chromatography (TLC) of the 
promising extract, fraction, sub-fraction 
To identify some of the classes of 
compounds present in the promising plant 
extracts and that might be individually or 
collectively responsible for the anti-yeast 
activity observed, a phytochemical screening 
was performed. This study was conducted 
following the protocols previously described 
(Sofowora, 1993; Trease and Evans, 1996; 
Oloyede, 2005), to screen the presence of 
biologically active classes of secondary 
metabolites, including alkaloids, phenols, 
tannins, saponins, flavonoids, glycosides. 
Besides, the crude extract (UCl), 
fraction (UCl EtOH CH2Cl2), and sub-fraction 
(FS: 237-253) were eluted on a TLC format 
using Hexane/Ethyl Acetate (Hex/EtOAc) and 
Methylene chloride/Methanol (CH2Cl2/MeOH) 
solvent systems and visualized under UV 
(254-365 nm) to achieve their profiles. 
 
Statistical analysis  
The data were statistically analysed 
using the software SPSS 17.0 for Windows 
and analysis of variance (ANOVA) coupled 
with turkey test. A p<0.05 was considered as 
statistically significant.  
 
RESULTS    
Plant extraction and fractionation 
The yields of plant extraction ranged 
from 1.96% to 6.77% for the aqueous extracts 
and from 7.79% to 10.67% for the ethanolic 
extracts. From the 4 ethanolic and 4 aqueous 
crude extracts, partition using hexane, 
methylene chloride and methanol afforded 12 
and 16 fractions/interfaces respectively. 
All the extracts and fractions were 
screened for biological activity against yeasts, 
and the methylene chloride fraction (UCl 
EtOH CH2Cl2) from the leaf ethanolic extract 
with the best anti-yeast potency was selected 
for further bio-guided study. The fractionation 
of UCl EtOH  CH2Cl2 led to 19 sub-fractions: 
FA: 1–11; FB: 12–17; FC: 18–28; FD: 29–35; 
FE: 36–50; FF: 51–57; FG: 58–64; FH: 65–
81; FI: 82–86; FJ: 87–98; FK: 99–111; FL: 
112–117; FM: 118–126; FN: 127–133; FO: 
134–155; FP: 156–164; FQ: 165–178; FR: 
179–236 and FS: 237–253 that were similarly 
screened against the tested yeasts.  
 
Anti-yeast activity of extracts, fractions and 
sub-fractions 
The results obtained from the in vitro 
anti-yeast screening of aqueous and ethanolic 
crude extracts of U. calophyllum indicated 
concentration-dependent activity as shown in 
Figure 1. This Figure 1 summarizes the results 
obtained for the more promising extract (UCl 
EtOH), fraction (UCl EtOH CH2Cl2), and sub-
fraction (Sub-fraction FS: 237-253). The 
complete dataset is provided in Table 1. 
Overall, the MIC values ranged from 0.63 to 
30 mg/mL with the best potency being for the 
ethanolic extract of U. calophyllum leaf that 
showed cidal effect against all the tested 
yeasts, with the exception of C. glabrata and 
Cr. neoformans. 
Fractions afforded from crude extracts 
showed MIC values ranging from 1.25 to >10 
mg/mL on the tested yeasts, with the 
methylene chloride fraction of the leaf 
ethanolic extract (UCl EtOH CH2Cl2) 
exhibiting the best activity on all the tested 
yeasts (MIC values ranging from 1.25-2.5 
mg/mL). This fraction was selected and 
submitted to further bio-guided fractionation. 
From the results obtained, the 
afforded sub-fractions exhibited varying 
levels of activity, with MIC values ranging 
from 0.0625 to ≥2 mg/mL with respect to the 
microorganism tested. Sub-fraction FS: 237-
253 (obtained with 100% Methanol) exhibited 
the overall best activity on all the tested 
microorganisms with MIC values ranging 
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from 0.0625 mg/mL to 0.25 mg/mL. The C. 
albicans isolate showed particular sensitivity 
to this sub-fraction with a MIC of 0.0625 
mg/mL. Overall, following the criteria stated 
above (Carbonnelle et al., 1987), it exerted 
cidal effect at concentrations tested against 7 
out of the 8 yeasts, with the exception for C. 
parapsilosis where the action was fungistatic.  
Based on this activity profile of sub-fraction 
FS: 237-253, it was submitted to studies of 
phenotypic mechanisms of action. 
 
Time-kill Kinetics and inhibition of 
phenotypic changes 
Time-kill Kinetics 
Figure 2 shows the induced 
concentration-dependent effect of sub-fraction 
FS: 237-253 on the variation of colony 
forming units of C. albicans NR-29445 (A) 
and C. albicans NR-29450 (B) within 24 h. 
Sub-fraction FS: 237-253 at 0.125 mg/mL and 
0.25 mg/mL exerted significant inhibitory 
effects on C. albicans NR-29450 within 24 h. 
However, the cidal effect could be observed 
only at 0.25 mg/mL around 12-16 h of 
incubation. On the other hand, C. albicans 
NR-29445 showed to be relatively less 
sensitive to the sub-fraction than C. albicans 
NR-29450, as otherwise proven by the MICs 
of this sub-fraction against the two strains 
(0.125 mg/mL and 0.25 mg/mL respectively). 
Fungicidal effect was however apparent at 
0.25 mg/mL at the edge of 24 h. 
Inhibition of phenotypic changes: germ-tube 
formation (GTF), filamentation and 
chlamydosporulation, biofilm formation 
The inhibitory effect of sub-fraction 
FS: 237-253 on the ability of C. albicans NR-
29445 and NR-29450 to form germ tubes was 
assessed. From the results obtained, no germ 
tube was formed by C. albicans NR-29450 in 
the presence of sub-fraction FS: 237-253 at 
0.125 mg/mL and 0.25 mg/mL. However, 
germ tubes were present at lower 
concentration, but less apparent than in the 
negative control. Concerning C. albicans NR-
29445, inhibition of GTF could be observed 
only at 0.25 mg/mL. The inhibition of 
filamentation was observed with sub-fraction 
FS: 237-253 at 0.25 mg/mL on Candida 
albicans NR-29450 and 0.125 mg/mL on C. 
albicans NR-29445. Filamentation of yeast 
cells to hyphal growth is directly linked to its 
pathogenicity and cells that cannot undergo 
transition are known to be avirulent. In 
addition, inhibition of chlamydosporulation 
was observed at 0.0625 mg/mL, 0.125 
mg/mL, and 0.25 mg/mL. The result obtained 
with the sub-fraction at 0.125 mg/mL against 
C. albicans NR-29445 is shown in Figure 3. 
This figure shows a significant 
degradation of the hyphae-chlamydospores 
system of C. albicans NR-29445 in the 
presence of sub-fraction FS: 237-253 at 0.125 
mg/mL, compared to the negative control. 
The results obtained from biofilm 
inhibition assay (Figure 4) showed very 
moderate inhibition by the sub-fraction at 0.25 
mg/mL relative to the control containing no 
drug. This is an indication that at 
concentrations tested the sub-fraction FS: 237-
253 has no effect on biofilm production by C.
albicans NR-29450. 
Qualitative phytochemical composition of the 
promising extract, fraction, and sub-fraction 
The qualitative phytochemical 
composition of the most promising extract 
(UCl EtOH), fraction (UCl EtOH CH2Cl2) 
and sub-fraction (Sub-fraction FS: 237-253) 
obtained from the leaf of U. calophyllum is 
given in Table 2. Results indicate that all the 
screened classes of secondary metabolites are 
present in the crude ethanolic extract. Further 
fractionation of this extract led to a less 
complex sub-fraction (Sub-fraction FS: 237-
253) containing only terpenoids, flavonoids, 
and glycosides. 
The comparative TLC profiles of the 
crude extract (UCl), fraction (UCl EtOH 
CH2Cl2), and sub-fraction (FS: 237-253) of 
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the leaf extract of U. calophyllum are 
presented in Figure 5. 
From this Figure 5, it appears that the 
crude extract and fraction are densely rich in 
secondary metabolites compared to the sub-
fraction that presents only two clearly defined 
spots under UV visualization. It should also 
be noted that the sub-fraction was not 
significantly eluted by the solvent system 
Hex/EtOAc 25/75. Rather, this could be 
achieved with a more polar system 
(CH2Cl2/MeOH 20/80), suggesting that the 
secondary metabolites of U. calophyllum leaf 
extract responsible of the highest anti-yeast 








Figure 1: Activity parameters (MIC (A) and MFC (B)) of the most promising extract, fraction and 
sub-fraction. The plotted values represent means of duplicate experiments. Non prohibitive SD was 
















Figure 2: Time-dependent inhibition of C. albicans NR-29445 (A) and NR-29450 (B) at different 
concentrations of sub-fraction FS: 237 -253. The plotted values are means of results from duplicate 











Figure 3: Hyphae and chlamydospores of C. albicans NR-29445 in the A: absence of 











Figure 4: Effect of sub-fraction FS : 237 -253 against biofilm formation by C. albicans NR-29450. 
The plant extract was tested in duplicate at different concentrations. Average OD were plotted versus extract concentration. 






Figure 5: TLC profile of U. calophyllum leaf extract, fraction, and sub-fraction eluting 
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Field isolates Reference C. albicans strains 




 NR-29450 NR-29451 NR-29444 NR-29445 
Activity ± SD (mg/mL) 
  Crude extracts 
UCl EtOH MIC 1.25±0.54 0.63±0.27** 2.19±1.43 0.78±0.27* 3.75±0.00 1.88±0.00 3.75±0.00 3.75±0.00 
MFC 1.88±0.00* 5.00±2.16 7.50±0.00 3.75±0.00 15.00±. 0 7.50±0.00 15.00±0.00 15.00±0.00 
MFC/MIC 1.5 8 3.4 4.8 4 4 4 4 
UCtw EtOH MIC 1.88±0.00* 2.81±1.08 3.75±0.00 3.28±0.94 15.00±.00 30.00±0.00 30.00±0.00 15.00±0.00 
MFC 3.75±0.00 15.00±0.00 15.00±0.00 15.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 2 5 4 4.5 ND ND ND ND 
UCst EtOH MIC 5.00±2.17 5.60±2.17 12.50±4.33 6.56±1.88 7.50±0. 0 7.50±0.00 7.50±0.00 15.00±0.00 
MFC 7.50±0.00 7.50±0.00 12.50±0.00 30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 1.5 1.33 1 4.6 ND ND ND ND 
UCsb EtOH MIC 3.75±0.00 2.50±1.08 6.25±2.17 5.63±2.17 7.50±0.0 15.00±0.00 7.50±0.00 15.00±0.00 
MFC 7.50±0.00 15.00±0.00 15.00±0.00 30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 2 6 2.4 5.3 ND ND ND ND 
UCl aqueous MIC 7.50±0.00 3.75±0.00 7.50±0.00 1.88±0.00 15.00±0. 0 15.00±0.00 15.00±0.00 15.00±0.00 
MFC 7.50±0.00 7.50±0.00 7.50±0.00 7.50±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 1 2 1 3.9 ND ND ND ND 
UCtw aqueous MIC 3.75±0.00 0.94±0.00 15.00±0.00 7.50±0.00 7.50±0. 0 7.50±0.00 7.50±0.00 15.00±0.00 
MFC 7.50±0.00 7.50±0.00 15.00±0.00 15.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 2 8 1 2 ND ND ND ND 
UCst aqueous MIC 3.75±0.00 1.88±0.00 7.50±0.00 7.50±0.00 15.00±0. 0 ND 7.50±0.00 15.00±0.00 
MFC 7.50±0.00 7.50±0.00 7.5±0.00 30.00±0.00 ˃30.00±0.00 ND ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 2 4 1.5 4 ND ND ND ND 
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UCsb aqueous MIC 15.00±0.00 7.50±0.00 7.50±0.00 15.00±0.00 7.50±0. 0 15.00±0.00 7.50±0.00 7.50±0.00 
MFC 15.00±0.00 7.50±0.00 7.50±0.00 30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 ˃30.00±0.00 
MFC/MIC 1 1 1 2 ND ND ND ND 
Fractions 
UCl EtOH Hexane MIC 7.60±0.00 ˃7.60±0.00 7.60±0.00 ˃7.60±0.00 3.80±0.00 1.90±0.00* 3.80±0.00 1.90±0.00* 
MFC ˃7.60±0.00 ˃7.60±0.00 7.60±0.00 ˃7.60±0.00 3.80±0.00 7.60±0.00 3.80±0.00 3.80±0.00 
MFC/MIC ND ND 1 ND 1 4 1 2 
UCtw EtOH Hexane MIC 10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 10.00±0.00 2.50±0.00 2.50±0.00 5.00±0.00 5.00±0.00 
MFC 10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC 1 ND ND ND 2 2 1 1 
UCst EtOH Hexane MIC 5.00±0.00 ˃10.00±0.00 5.00±0.00 10.00±0.00 5.00±0.00 2.50±0.00 2.50±0.00 2.50±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC ND ND ND ND 1 2 2 2 
UCsb EtOH Hexane MIC 10.00±0.00 5.00±0.00 5.00±0.00 10.00±0.00 5.00±0. 0 5.00±0.00 2.50±0.00 2.50±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC ND ND ND ND 1 1 2 2 
UCl EtOH CH 2Cl2 MIC 2.50±0.00 2.50±0.00 1.25±0.00** 2.50±0.00 1.25±0.00** 1.25±0.00** 1.25±0.00** 1.25±0.00** 
MFC 5.00±0.00 ˃5.00±0.00 5.00±0.00 ˃5.00±.00 5.00±0.00 5.00±0.00 5.00±0.00 ˃5.00±.00 
MFC/MIC 2 ND 4 ND 4 4 4 ND 
UCtw EtOH CH 2Cl2 MIC 6.67±0.00 6.67±0.00 6.67±0.00 ˃6.67±0.00 3.33±0.00 3.33±0.00 6.67±0.00 3.33±0.00 
MFC ˃6.67±0.00 ˃6.67±0.00 ˃6.67±0.00 ˃6.67±0.00 6.67±0.00 3.34±0.00 3.34±0.00 3.34±0.00 
MFC/MIC ND ND ND ND 2 1 1 1 
UCsb EtOH CH2Cl2 MIC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 2.50±0.00 5.00±0.00 10.00±0.00 10.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 10.00±0.00 5.00±0.00 10.00±0.00 10.00±0.00 
MFC/MIC ND ND ND ND 4 1 1 1 
UCtw aqueous CH2Cl2 MIC ˃10.00±0.00 ˃10.00±0.00 10.00±0.00 ˃10.00±0.00 2.50±0.00 2.50±0.00 2.50±0.00 2.50±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 10.00±0.00 ˃10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC ND ND 1 ND 2 2 2 2 
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UCsb aqueous CH2Cl2 MIC 10.00±0.00 ˃10.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 5.00±0.00 5.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10±0.00 ˃10.00±.00 ˃10.00±.00 ˃10.00±.00 ˃10.00±.00 
MFC/MIC ND ND ND ND ND ND ND ND 
UCl EtOH MeOH MIC 10.00±0.00 ˃10.00±0.00 5.00±0.00 ˃10.00±0.00 2.50±0.00 5.00±0.00 10.00±0.00 2.50±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC ND ND ND ND ND ND ND ND 
UCtw EtOH MeOH MIC 10.00±0.00 ˃10.00±0.00 10.00±0.00 10.00±0.00 2.50±0.00 2.50±0.00 5.00±0.00 5.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC ND ND ND ND 2 2 1 1 
UCst EtOH MeOH MIC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 2.50±0.00 5.00±0.00 10.00±0.00 10.00±0.00 
 MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 5.00±0.00 5.00±0.00 10.00±0.00 10.00±0.00 
  MFC/MIC ND ND ND ND 2 1 1 1 
UCsb EtOH MeOH MIC 10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 5.00±0.00 10.00±0.00 5.00±0.00 2.50±0.00 2.50±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 10.00±0.00 5.00±0.00 5.00±0.00 5.00±0.00 
MFC/MIC ND ND ND ND 1 1 1 1 
UCl aqueous interface MIC 5.00±0.00 10.00±0.00 5.00±0.00 5.00±0.00 5.00±0. 0 10.00±0.00 10.00±0.00 5.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC ND ND ND ND ND ND ND ND 
UCtw aqueous interface MIC 5.00±0.00 10.00±0.00 5.00±0.00 5.00±0.00 5.00±0. 0 5.00±0.00 2.50±0.00 5.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC ND ND ND ND ND ND ND ND 
UCsb aqueous interface MIC 10.00±0.00 5.00±0.00 5.00±0.00 10.00±0.00 1.25±0.00** 2.50±0.00 2.50±0.00 2.50±0.00 
MFC 10.00±0.00 10.00±0.00 ˃10.00±0.00 10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC 1 2 ND 1 ND ND ND ND 
UCl aqueous MeOH MIC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 10.00±0.00 ˃10.00±.00 ˃10.00±.00 ˃10±.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC ND ND ND ND ND ND ND ND 
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UCtw aqueous MeOH MIC 10.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 5.00±0.00 10.00±0.00 
MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 
MFC/MIC ND ND ND ND ND ND ND ND 
UCsb aqueous MeOH MIC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 5.00±0.00 5.00±0.00 10.00±0.00 10.00±0.00 
 MFC ˃10.00±0.00 ˃10.00±0.00 ˃10.00±0.00 ˃6.25±0.00 5.00±0.00 10.00±0.00 10.00±0.00 10.00±0.00 
  MFC/MIC ND ND ND ND 1 2 1 1 
Sub-fractions of  UCl EtOH CH2Cl2 fraction 
FA : 1-11 MIC 2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 2.00±0.0 2.00±0.00 2.00±0.00 2.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 ND ND ND 1 
FB: 12-17 MIC 2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 2.00±0.0 2.00±0.00 1.00±0.00 2.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 ND ND ND 1 
FC :18-28 MIC 2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 2.00±0.0 2.00±0.00 2.00±0.00 2.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 ND ND ND 1 
FD : 29-35 MIC 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.0 2.00±0.00 2.00±0.00 2.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 ND ND ND 1 
FE : 36-50 MIC 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 1.00±0.0 2.00±0.00 1.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 2 1 ND 2 
FF : 51-57 MIC 2.00±0.00 0.50±0.00 1.00±0.00 2.00±0.00 1.00±0.0 2.00±0.00 1.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 4 2 1 ND ND ND 2 
FG :58-64 MIC 2.00±0.00 1.00±0.00 1.00±0.00 0.50±0.00* 2.00±0.00 2.00±0.00 2.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
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MFC/MIC ND 2 1 2 ND ND ND 2 
FH : 65-81 MIC 2.00±0.00 1.00±0.00 1.00±0.00 0.50±0.00 2.00±0.0 2.00±0.00 2.00±0.00 1.00±0.00 
MFC 2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC 1 2 1 2 ND ND ND 2 
FI : 82-86 MIC 2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 2.00±0.0 2.00±0.00 2.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 1 1 1 ND ND ND 2 
FJ :87-98 MIC 2.00±0.00 0.50±0.00* 0.125±0.00** 0.125±0.00** 1.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 
MFC ND 1.00±0.00 1.00±0.00 0.25±0.00* ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 2 8 2 ND ND ND 2 
FK: 99-111 MIC 1.00±0.00 0.25±0.00* 0.25±0.00* 0.25±0.00* 0.50±0.00* 1.00±0.00 0.50±0.00* 1.00±0.00 
MFC ND 1.00±0.00 1.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC ND 4 4 4 ND ND ND 2 
  MIC 2.00±0.00 2.00±0.00 2.00±0.00 0.50±0.00 2.00±0.0 2.00±0.00 2.00±0.00 1.00±0.00 
FL:112-117 MFC ND 2.00±0.00 2.00±0.00 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
  MFC/MIC ND 1 1 2 ND ND ND 2 
FM:118-126 MIC 1.00±0.00 0.50±0.00* 0.25±0.00* 0.125±0.00* 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 
MFC 1.00±0.00 1.00±0.00 0.50±0.00* 1.00±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 2.00±0.00 
MFC/MIC 1 2 2 8 ND ND 2 2 
FN: 127-133 MIC 1.00±0.00 0.50±0.00* 0.25±0.00* 0.25±0.00* 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 1.00±0.00 1.00±0.00 0.50±0.00 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 2.00±0.00 
MFC/MIC ND 2 4 2 ND ND 2 2 
FO:134-155 MIC 1.00±0.00 0.50±0.00* 0.50±0.00* 0.50±0.00* 1.00±0.00 2.00±0.00 1.00±0.00 1.00±0.00 
MFC ˃2.00±0.00 0.50±0.00* 1.00±0.00 0.50±0.00* ˃2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 
MFC/MIC ND 1 2 1 ND 1 1 2 
FP:156-164 MIC 1.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.0 2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.00 2.00±0.0 >2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC 2 1 1 1 1 ND ND 1 
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FQ:165-178 MIC 1.00±0.00 2.00±0.00 2.00±0.00 0.50±0.00 2.00±0.0 ˃2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC 2.00±0.00 2.00±0.00 2.00±0.00 0.50±0.00 2.00±0.0 >2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC/MIC 2 1 1 1 1 ND ND 1 
FR:179-236 MIC 2.00±0.00 1.00±0.00 ˃2.00±0.00 1.00±0.00 2.00±0.00 2.00±0.00 ˃2.00±0.00 2.00±0.00 
MFC >2.00±0.00 2.00±0.00 >2.00±0.00 >2.00±0.00 >2.00±0.00 >2.00±0.00 >2.00±0.00 >2.00±0.00 
MFC/MIC ND 2 ND ND ND ND ND ND 
FS:237-253 MIC 0.0625±0.00*** 0.25±0.00* 0.125±0.00** 0.25±0.00* 0.125±0.00** 0.25±0.00* 0.125±0.00** 0.25±0.00* 
MFC 0.25±0.00* 0.25±0.00* 1.00±0.00 0.25±0.00* 0.50±0.00* 0.50±0.00* 0.50±0.00* 1.00±0.00 
MFC/MIC 4 1 8 1 4 2 4 4 
Positive control 
(Nystatin) 
MIC 0.0156±0.00 0.0078±0.00 0.0078±0.00 0.0156±0.00 .0078±0.00 0.0039±0.00 0.0078±0.00 0.002±0.00 
MFC 0.0156±0.00 0.031±0.00 0.0156±0.00 0.0625±0.00 .031±0.00 0.031±0.00 0.0156±0.00 0.031±0.00 
MFC/MIC 1 4 2 4 4.2 8 2.05 16 
 *indicate P≤0.05, **P≤0.01, ***P≤0.001 
MIC: Minimum Inhibitory Concentration; MFC: Minimum Fungicidal Concentration; SD: Standard Deviation; ND: not determined,  UCl EtOH : Ethanolic extract of U. calophyllum leaves; UCtw EtOH : 
Ethanolic extract of U. calophyllum twigs; UCst EtOH : Ethanolic extract of U. calophyllum stem; UCsb EtOH : Ethanolic extract of U. calophyllum stem bark; UCl aqueous: aqueous extract of U. 
calophyllum leaves; UCtw aqueous: aqueous extract of U. calophyllum twigs; UCst aqueous: aqueous extract of U. calophyllum stem; UCsb aqueous : aqueous extract of U. calophyllum stem bark; UCl EtOH 
Hexane: Hexane fraction of the ethanolic extract of U.calophyllum leaves ; UCl EtOH CH2Cl2 : Methylene Chloride Fraction of the ethanolic extrac  of of U. calophyllum leaves ; UCl EtOH MeOH : 
Methanol extract of the ethanolic extract of U. calophyllum leaves ;  UCtw EtOH Hexane : Hexane fraction of the ethanolic extract of U. calophyllum twigs ; UCtw EtOH CH2Cl2: Methylene Chloride 
Fraction of the ethanolic extract of of U. calophyllum twigs ; UCtw EtOH MeOH: Methanol fraction of the ethanolic extract of U. calophyllum twigs ;  UCst EtOH Hexane : Hexane fraction of the ethanolic 
extract of U. calophyllum stem; UCst EtOH CH2Cl2  : Methylene chloride fraction of the ethanolic extract of U. calophyllum stem; UCst EtOH MeOH : Methanol fraction of the ethanolic extract of U. 
calophyllum stem ; UCsb EtOH Hexane : Hexane fraction of the etanolic extract of U. calophyllum stem bark ; UCsb EtOH CH2Cl2 : Methylene chloride fraction of the ethanolic extract of U. calophyllum 
stem bark ; UCsb EtOH MeOH : Methanol fraction of the ethanolic extract of U. calophyllum stem bark; UCl aqueous interface: Interface  fraction of the aqueous extract of U. calophyllum leaves ; UCl 
aqueous MeOH : Methanol Fraction of the aqueous extract of U. calophyllum leaves ; UCtw aqueous CH2Cl2: Methylene chloride fraction of the aqueous extract of aqueous extract of U. calophyllum twigs ; 
UCtw aqueous interface: Interface fraction of the aqueous extract of the aqueous extract of U. calophyllum twigs ; UCtw aqueous MeOH: Methanol fraction of theaqueous extract of the aqueous extract of U. 
calophyllum twigs  ; UCsb aqueous CH2Cl2 : Methylene chloride of the  aqueous extract of U. calophyllum stem bark ; UCsb aqueous interface:  Interface fraction of the aqueous extract of U. calophyllum 
stem bark ; UCsb aqueous MeOH : Methanol fraction of the aqueous extract of U. calophyllum stem bark.  
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Table 2: Qualitative phytochemical composition of the most promising extracts, fraction and sub-
fraction. 
 
Extracts Alkaloids Terpenoids Tannins Saponins Flavonoids Glycosides 
UCl EtOH + + + + + + 
UCl EtOH CH 2Cl2 + + + - + + 
Sub-fraction FS:237-253 - + - - + + 
Legend: (+) Present, (-) Absent 
 
 
DISCUSSION      
The aqueous and ethanolic extracts 
of U. calophyllum showed significant anti-
yeast potency against the tested isolates and 
strains. These results support the use of this 
plant by practitioners of indigenous medicine 
(Masoko et al., 2010). The MIC values of the 
ethanolic extracts of leaf and twig against C. 
albicans (1.25 and 1.88 mg/mL respectively) 
and C. glabrata (0.63 and 2.81 mg/mL 
respectively) showed slight difference from 
the results previously obtained with the same 
extracts (Zeuko’ o et al., 2012) on the same 
yeasts (C. albicans 2.61; 2.08 and C. glabrata 
2.08). These disparities could be due to 
differences in the inoculum size and 
methodological approaches used.  
The essence of bioactive plant extract 
fractionation is to concentrate the active 
principle to result in activity improvement 
(Firas and Al-Bayati, 2008; Nwodo et al., 
2011). In the particular case of this study, the 
most active crude extract (UCl EtOH) showed 
MIC values ranging from 0.63-3.75 mg/mL 
against the tested yeasts. Partition of the crude 
extract led to the more promising fraction 
(UCl EtOH CH2Cl2) with the range of activity 
being 1.25-2.50 mg/mL. Further fractionation 
afforded sub-fractions with MIC ranging 
below 2 mg/mL, the most potent having an 
MIC as low as 0.0625 mg/mL, to say 10 fold 
more active than the original crude extract. It 
is therefore relevant to note that fractionation 
of U. calophyllum leaf crude extract has 
increased the activity.  
Given the results obtained with sub-
faction FS: 237-253, its effect was studied on 
the morphological stages of C. albicans (C. 
albicans NR-29450 and C. albicans NR-
29445). The variation of colony forming units 
at different concentrations of the sub-fraction 
showed to be significant with more 
pronounced action against C. albicans NR-
29450 at 0.25-0.0125 mg/mL and cidal effect 
at 0.25 mg/mL after 8 hours of contact.  At 
these concentrations, C. albicans NR-29445 
showed reduced sensitivity. 
Establishing whether an agent has 
fungistatic or fungicidal properties provides 
valuable information on the potential action of 
antifungal agents in-vitro. However, it is 
necessary to combine this information with 
pharmacokinetic/pharmacodynamic data in 
order to provide more meaningful prediction 
of efficacy in vivo.  
On the other hand, the ability of C. 
albicans to undergo morphogenetic 
conversion from yeast to pseudo- hyphae then 
hyphae contributes to disease establishment 
and progression (Navarro-Garcia et al., 2001; 
Berman and Sudbery, 2002; Banerjee et al., 
2008). In addition, this yeast to hyphae 
transition is necessary for biofilm formation 
and filamentation that is an essential 
component of mature biofilms. Biofilm 
formation and filamentation of C. albicans are 
being increasingly recognized as the main 
virulence factors contributing to the 
pathogenesis of candidiasis. The inhibition of 
filamentation and chlamydosporulation 
exerted by sub-faction FS: 237-253 therefore 
underscores its mechanism of action and 
emphasizes its potential for the development 
of new antifungal agents (Baillie and Douglas, 
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1999; Lopez-Ribot, 2005; Nobile et al., 2008).  
Moreover, sub-fraction FS: 237-253 inhibited 
germ tube formation by C. albicans NR-
29450 at 0.125 mg/mL and 0.25 mg/mL. GTF 
is a morphological characteristic that increases 
the ability of the fungi to adhere and penetrate 
into infected tissue (Cutler, 1991). It has been 
suggested as a potential virulence factor in the 
pathogenesis of C. albicans (Sudbery et al., 
2004), since it is the first stage of true hyphae 
development. The ability to change 
morphology from the yeast form to hyphae 
(and vice versa) is thought to be the primary 
cause of the C. albicans pathogenicity   (Lee 
et al., 2005).  
Additionally, the formation of hyphae 
(Liu et al., 1994) and biofilms (Fanning and 
Mitchell, 2012), added to the integrity of the 
cell wall (Kelly et al., 2004), the rapid 
adaptive capacity to external environmental 
conditions (Brown et al., 2012) all contribute 
to virulence.  During morphogenesis, cells 
may switch to filamentous growth and 
develop elongated suspensor cells that give 
rise to chlamydospores (Martin et al., 2005). 
The functions of chlamydospores for the 
biology and possibly for the virulence of C. 
albicans are unclear. The inhibition of 
chlamydospores by sub-faction FS: 237-253 
further emphasizes its ability to stop yeast 
cells switching to filamentous growth thereby 
blocking the production of biofilms (Sudbery, 
2011). 
Biofilm production could be 
moderately inhibited by sub-fraction FS: 237-
253 at 0.25 mg/mL. Biofilm formation is a 
complex, multicellular process, consisting of 
cell adhesion, growth, morphogenic switching 
between yeast and filamentous states, and 
quorum sensing (Deveau and Hogan, 2011). 
Adhesion of C. albicans cells to materials or 
host cells is a prerequisite for biofilm 
formation, and cell-cell interactions may be 
important in the hierarchical organization of 
cells within the biofilm (Ramage et al., 2005).   
Phytomedicines are the mainstay of 
traditional system of healing in developing 
countries, usually integrated to cultural 
believes. This approach is becoming part of 
the integrative healthcare system known as 
complementary and alternative system of 
medicines. Moreover, identification of the 
active principles of these phytomedicines is a 
critical step towards the standardization of 
their production. In addition, these active 
principles may act individually or collectively 
to produce the observed beneficial effects. 
The biological activities of some of these 
principles have been reported. The 
phytochemical analysis of the most interesting 
sub-fraction indicated the presence of 
terpenoids, flavonoids, and glycosides. The 
mechanism of action of terpenoids is not fully 
understood but is speculated to involve 
membrane disruption by the lipophilic 
compounds (Cowan, 1999). Flavonoids have 
the ability to complex with extra-cellular and 
soluble proteins present on the microbial cell 
wall and leading to the inactivation of these 
proteins, thereby causing loss of their function 
(Mason and Wasserman, 1987). The 
glycosides are thought to act through the 
formation of ion channels in the microbial 
membrane (Terras et al., 1993; Zhang and 
Lewis, 1997) or competitive inhibition of 
adhesion of microbial proteins to host 
polysaccharide receptors (Sharon and Ofek, 
1986). The cidal effect exerted by sub-fraction 
FS: 237-253 might be due to the mechanisms 
of these components. 
 
Conclusion 
This work has investigated the anti-
yeast activity of extracts and fractions from 
the twig, stem, stem bark and leaf of U. 
calophyllum. Results showed that the leaf 
extract and subsequent fractions possess 
potent anti-yeast properties, more likely due to 
the quality of their secondary metabolites 
contents. Most of the promising extracts, 
fractions, and sub-fractions demonstrated 
fungicidal potential, emphasizing their 
potential as source of anti-yeast agents with 
innovative mode of action. Meanwhile, to 
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develop alternative therapies against mycoses 
based on these starting points, further detailed 
investigations are required to characterize the 
active ingredients and study their 
pharmacological and toxicological properties. 
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